Our experienced teams support development and commercialization of our products from discovery to market independently as well as with strategic partners.
Conditionally Active Biologics, or CABs, were pioneered by our partner, BioAtla (NASDAQ: BCAB). The CAB platform is designed to create antibodies that have a widened therapeutic window, or TI. What this means is that antibodies can be made to be safer, while still maintaining or even increasing potency.
The CAB platform takes advantage of the special characteristics of the tumor microenvironment, or TME. Due to the cell metabolism of cancerous tissue, the TME has a lower pH than healthy parts of the body. Antibodies designed using the CAB platform are able to recognize this pH and bind tightly when near a tumor, while remaining inactive outside the TME. Importantly, this chemical switch is reversible, which means that the antibodies are switched “off” away from the tumor, even if they enter and exit the TME multiple times. This allows for more on-target binding and avoids off-target binding, resulting in the widened TI.
By using this platform, we have a deep pipeline of product candidates that target a range of validated proteins expressed on tumor cells. The broad applicability of the CAB technology also means that these antibodies can be designed as antibody-drug conjugates, or ADCs, or bispecifics.
Our two lead candidates target AXL and ROR2. Both have preclinical and phase 1 data supporting the CAB hypothesis, and interim phase 2 data from multiple ongoing global clinical trials have provided exciting data in sarcoma, which is notoriously difficult to treat and has no approved first line treatment. In addition, encouraging signals in melanoma and non-small cell lung cancer, or NSCLC, has included complete responses, or CRs, in both indications.
To learn more, please visit our collaboration partner’s website here.